Background/Purpose: Clopidogrel is associated with a high incidence of upper gastrointestinal bleeding in high-risk patients. However, the characteristic upper gastrointestinal lesions in symptomatic clopidogrel users remain unclear. The aims of this study were to investigate the characteristics of endoscopic findings in clopidogrel users undergoing endoscopy for upper gastrointestinal symptoms and to compare the clinical characteristics and upper gastrointestinal lesions between symptomatic clopidogrel and aspirin users. Methods: This observational study included 215 consecutive patients receiving clopidogrel (n Z 106) or low-dose aspirin (n Z 109) therapy who underwent endoscopy for dyspeptic symptoms. The upper gastrointestinal lesions were carefully assessed, and a complete medical history was obtained by a standard questionnaire. Results: The frequencies of hemorrhagic spots, erosions and peptic ulcers in the symptomatic clopidogrel users were 25%, 39% and 39%, respectively. Among the peptic ulcer patients on clopidogrel therapy, the distributions of ulcers were 78%, 5% and 17% in the stomach, duodenum and both, respectively. Compared with the aspirin group, the clopidogrel group was older and had higher frequencies of past ulcer history and past gastrointestinal bleeding history in their clinical characteristics. By contrast, the clopidogrel users had a lower prevalence of active Helicobacter pylori infection than aspirin users (17% vs. 35%, respectively, p Z 0.007). Regarding to the endoscopic findings, the clopidogrel users had higher frequencies of hemorrhagic spots (25% vs. 10%) and peptic ulcer (39% vs. 24%) than aspirin users (p Z 0.004 and 0.027, respectively). Conclusion: Most peptic ulcers in clopidogrel users are located in the stomach. The frequencies of hemorrhagic spots and peptic ulcers in symptomatic clopidogrel users are higher than those in symptomatic aspirin users.
Introduction
Antiplatelet agents such as aspirin and clopidogrel are widely used for primary and secondary prevention of cardiovascular and cerebrovascular diseases. 1 However, use of either aspirin or clopidogrel is associated with adverse gastrointestinal effects. Aspirin irreversibly inhibits cyclo-oxygenase (COX) activity in both platelet and gastrointestinal mucosa. Thus, the synthesis of cytoprotective prostaglandin in the gastrointestinal tract is reduced, and gastroduodenal lesions can subsequently develop. 2 Endoscopic study of asymptomatic mini-dose aspirin ( 100 mg/day) users revealed that ulcers or erosions developed in 48% of patients. 3 A multinational prospective study of 187 patients given low-dose aspirin (75e325 mg daily) for prophylaxis of cardiovascular diseases revealed that 20% had dyspeptic symptoms. The same population also had an 11% prevalence of gastric and duodenal ulcer. 4 In patients with aspirin allergy, aspirin intolerance or history of peptic ulcer, clopidogrel is a widely used alternative. This adenosine diphosphate (ADP) receptor antagonist inhibits platelet aggregation by irreversibly inhibiting ADP-induced activation of platelet fibrinogen (glycoprotein IIb/IIIa). 5 A recent study showed that clopidogrel induced less gastroduodenal injury than aspirin in healthy participants. 6 The Clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) trial involving 19,185 patients with mean follow-up of 1.91 years also demonstrated that clopidogrel (75 mg once daily) was associated with significantly less gastrointestinal hemorrhage (0.52% vs. 0.72%) and upper gastrointestinal disturbance (indigestion/nausea/ vomiting) (0.97% vs. 1.22%) than aspirin (325 mg once daily). 7 Nonetheless, a recent retrospective study reported a 12% frequency of clopidogrelassociated gastrointestinal bleeding in a high-risk population with previous peptic ulcer disease. 8 Currently, few studies have investigated the typical findings of gastrointestinal lesions associated with clopidogrel therapy, though the characteristics of the gastroduodenal lesions in aspirin therapy are well studied.
The aims of this prospective study were to investigate the characteristics of endoscopic findings in clopidogrel users undergoing endoscopy for upper gastrointestinal symptoms and to compare the clinical characteristics and upper gastrointestinal lesions between symptomatic clopidogrel and aspirin users.
Materials and methods

Patients
From January 2009 to December 2010, consecutive outpatients who had received either clopidogrel or aspirin therapies and underwent diagnostic endoscopy for dyspeptic symptoms were recruited. All of them had a medical history of regular clopidogrel or aspirin consumption within 1 month before endoscopy. The exclusion criteria included: (1) use of a proton pump inhibitor (PPI) or H 2 blocker within the past 1 month before endoscopy; (2) use of warfarin or ticlopidine within the past 1 month; (3) use of a non-steroidal antiinflammatory drug (NSAID) within the past 1 month; (4) lack of symptoms; (5) previous gastric operation; and (6) concomitant use of aspirin and clopidogrel.
Study design
Endoscopies were performed with the Olympus GIF XV10 and GIF XQ200 gastroscopes (Olympus Corp., Tokyo, Japan) after patients had fasted overnight. Upper gastrointestinal lesions were carefully examined and assessed according to the Lanza Endoscopic Scoring System. 9 The Lanza score is a categorical score (0e4) of endoscopic upper gastrointestinal erosion and ulcer and mucosal hemorrhage, defined as follows: score 0 Z normal stomach and proximal duodenum; 1 Z mucosal hemorrhage only; 2 Z one or two erosions; 3 Z three to ten erosions; 4 Z greater than ten erosions or an ulcer. Erosions were defined as flat whitebased mucosal breaks of any size, and ulcers were defined as mucosal breaks of 3 mm or more demonstrating unequivocal depth. Additionally, antrum biopsy was performed for the rapid urease test. 10 The following data were recorded for each participant: age, sex, medical history, corticosteroid use, history of smoking, alcohol, coffee and tea consumption, symptom score by questionnaires, history of H. pylori eradication, co-morbidity, and indication for the use of anti-platelet agents. Co-morbidity included hypertension, diabetes mellitus, cerebral vascular accident, coronary artery disease, congestive heart failure, cirrhosis and end-stage renal disease. Smoking was defined as consumption of one pack or more of cigarettes per week. Coffee or tea consumption was defined as drinking one cup or more per day. Symptoms of patients were assessed by a symptom score by Tucci et al. 11 Diagnosis of H. pylori infection was according to a positive result of rapid urease test. 12 
Gastrointestinal symptom assessments
A previously validated symptom questionnaire by Tucci et al., 11 with the symptom score ranging from zero to 12, was administered to each patient. The questionnaire assessed four well-categorized dyspeptic symptoms: epigastric pain or burning, postprandial fullness, nausea and vomiting. Each symptom was graded as 0e3 according to its influence on the patients' activities; 0 Z absent; 1 Z mild (not influencing the patient's activities); 2 Z relevant (diverting from, but not urging modifications of usual activities); and 3 Z severe (interfering with ordinary activities of the patients).
Rapid urease test
The rapid urease test was performed according to our previous study. 12 Each biopsy specimen was placed immediately in 1 mL of a 10% solution of urea in deionized water (pH 6.8) to which two drops of 1% phenol red solution was added, and incubated at 37 C for up to 24 hours. If the yellowish color around the area of inserted specimen changed to bright pink within the 24-hour limit, the urease test was considered positive. In our laboratory, the sensitivity and specificity of the rapid urease test are 96% and 91%, respectively. 12 
Statistical methods
All statistical analyses were performed with the SPSS program (version 12.0.1C; SPSS Inc. Chicago, UK, USA). The demographic and clinical characteristics of patients were compared by Student's t-test (for age and symptom score) or c 2 test with or without Yates correction (for gender, smoking, alcohol, coffee, tea, history of gastrointestinal bleeding, history of peptic ulcer and H. pylori status). The c 2 test or Fisher's exact test was used to evaluate the risk of peptic ulcer formation (univariate analysis). Those variables were subsequently assessed by a logistic regression method to identify independent risk factors for the development of peptic ulcer. All p values are two-sided. A p value <0.05 was considered to be significant.
Results
Four hundred and thirteen consecutive patients who had used either aspirin or clopidogrel within 1 month before endoscopy were examined. Of these, 198 were excluded for the following causes: (1) PPI or H 2 blocker use within the past 1 month (102 patients); (2) warfarin or ticlopidine use within the past 1 month (21 patients); (3) systemic NSAID use within the past 1 month (34 patients); (4) lack of symptoms (28 patients); (5) previous gastric operation (eight patients); and (6) concomitant use of aspirin and clopidogrel (five patients). Of the 215 eligible patients, 106 and 109 patients underwent clopidogrel and aspirin therapy, respectively. Regarding to the baseline characteristics, there were no significant differences in gender, tobacco use, alcohol use, coffee intake, tea consumption, co-morbidity, symptom score, and indication for the antiplatelet drugs between the aspirin and clopidogrel groups ( Table 1 ). Most patients who received anti-platelet agents did so for secondary prevention for the coronary artery events (68% vs. 75%, respectively, p Z 0.756). Compared with the aspirin group, the clopidogrel group was older (mean 73 years old vs. 69 years old, respectively, p Z 0.028) and had higher frequencies of past history of peptic ulcer (88% vs. 43%, respectively, p < 0.001), past history of gastrointestinal bleeding (32% vs. 17%, respectively, p Z 0.017), and past history of H. pylori eradication (26% vs. 14%, respectively, p Z 0.026). By contrast, the clopidogrel users had a lower frequency of active H. pylori infection than aspirin users (17% vs. 35%, respectively, p Z 0.007). Table 2 shows the endoscopic findings in symptomatic patients receiving clopidogrel or aspirin therapy. Clopidogrel users had higher frequencies of hemorrhagic spots (25% vs. 10%, p Z 0.004) and peptic ulcers (39% vs. 24%, p Z 0.027) than aspirin users. Additionally, the mean Lanza score in clopidogrel users was higher than that in aspirin users (2.4 vs. 1.9, p Z 0.043). Table 3 displays the characteristics of peptic ulcers in the patients receiving clopidogrel. In the clopidogrel users, the distributions of peptic ulcers were 78% (32/41), 5% (2/ 41) and 17% (7/41) in the stomach, duodenum and both, respectively. The mean diameter of ulcer in the clopidogrel group was larger than that in aspirin group (11 AE 7.1 mm and 7 AE 3.1 mm respectively, p Z 0.001). Most ulcers in symptomatic clopidogrel and aspirin users were located in the stomach. Fig. 1 demonstrates the typical endoscopic findings of the aspirin and clopidogrel groups. Univariate analyses demonstrated that history of smoking (p Z 0.003), past gastrointestinal bleeding history (p Z 0.001) and clopidogrel (p Z 0.027) were associated with the presence of peptic ulcer in patients who underwent clopidogrel or aspirin therapy. Advanced age, gender, alcohol use, past ulcer history, and current H. pylori infection were not associated with peptic ulcer risk (Table  4 ). Multivariate analysis revealed that history of smoking and past gastrointestinal bleeding history were two independent factors related to peptic ulcer risk in symptomatic patients who had undergone anti-platelet therapy, with odds ratios of 3.2 (95% CI 1.3e7.8) and 2.6 (95% CI 1.3e5.1), respectively ( Table 5 ).
Discussion
The current study showed that a significant number of symptomatic clopidogrel users had hemorrhagic spots (25%), erosions (39%) and peptic ulcers (39%). Most peptic ulcers in clopidogrel users were located in the stomach. Compared with symptomatic aspirin users, symptomatic clopidogrel users had higher frequencies of hemorrhagic spots and peptic ulcer. Additionally, the mean diameter of ulcer in symptomatic clopidogrel users was larger than that in aspirin users. These data indicate that gastroduodenal erosions or ulcers are common endoscopic findings in symptomatic clopidogrel users and endoscopic surveillance is warranted for symptomatic patients who undergo clopidogrel therapy.
Currently, the mechanisms of ulcer formation in patients receiving clopidogrel therapy are unclear. However, it has been hypothesized that ADP receptor antagonists may cause gastrointestinal injury through an impairment of ulcer healing. 13, 14 Platelet aggregation may play an important role in ulcer healing through the release of various platelet-derived growth factors that promote angiogenesis and ulcer healing. An animal study revealed that thrombocytopenic rats have impaired healing of gastric ulcers. 15 ADP receptor antagonists may impair gastric ulcer healing by suppressing the release of plateletderived growth factors. 15 In this study, the symptomatic clopidogrel users had higher frequencies of past history of peptic ulcer (88% vs. 43%, respectively, p < 0.001) and past history of gastrointestinal bleeding (32% vs. 17%, respectively, p Z 0.017) than symptomatic aspirin users. Because clopidogrel is much more expensive than aspirin, it is often reserved for the atherosclerotic patients with aspirin intolerance in clinical practice. According to the Guidelines of Taiwan Bureau of National Health Insurance, clopidogrel can be only prescribed for the patients with a history of peptic ulcer, aspirin allergy and aspirin intolerance. This strict regulation was possibly the most important factor that led to the demographic differences between symptomatic clopidogrel and aspirin users in this study.
Our study also showed that the clopidogrel users had a lower frequency of active H. pylori infection than aspirin users (17% vs. 35%, respectively). However, the frequency of past history of H. pylori eradication in the clopidogrel group was higher than that in the aspirin group (26.4% vs. 13.8%, respectively; p Z 0.026). We therefore proposed that the low frequency of active H. pylori infection in clopidogrel users was possibly due to previous anti-H. pylori therapy.
Although clopidogrel is less likely to induce gastrointestinal bleeding than aspirin, 16 the current study showed the clopidogrel users had higher prevalence of hemorrhagic spots and peptic ulcers. Additionally, the mean Lanza score in clopidogrel users was higher than that in aspirin users (2.4 vs. 1.9). The more severe gastroduodenal damage in symptomatic clopidogrel users might be due to the differences in the clinical background and ulcer diathesis between clopidogrel and aspirin users.
In this study, multivariate analyses revealed that history of smoking and past gastrointestinal bleeding history were two independent predictors of peptic ulcer in symptomatic patients who had undergone anti-platelet therapy with odd ratios of 3.2 and 2.6, respectively. Other clinical factors, such as advanced age, gender, alcohol consumption, history of peptic ulcer, and H. pylori status, did not affect the risk of peptic ulcer in symptomatic anti-platelet agent users. Previous studies also demonstrated that smoking is a risk factor for peptic ulcer disease and affects the healing of peptic ulcers. 16 Cigarette smokers are known to have decreased prostaglandin concentrations in gastric and duodenal mucosa, which is a possible mechanism of peptic ulcer formation and healing. 17 History of gastrointestinal bleeding was the other independent factor associated with ulcer development in this study. This finding is consistent with another independent study showing that history of gastrointestinal bleeding is associated with increased incidence of gastrointestinal bleeding in clopidogrel users. 18 In conclusion, hemorrhagic spots, gastroduodenal erosions and ulcers are common endoscopic findings in symptomatic clopidogrel users. Most peptic ulcers in clopidogrel users are located in the stomach. The frequencies of hemorrhagic spots and peptic ulcers in symptomatic clopidogrel users are higher than those in symptomatic aspirin users.
The patients who received clopidogrel had more hemorrhagic spots, peptic ulcers and higher Lanza score.
Smoking and past gastrointestinal bleeding history were two independent factors associated with the risk of peptic ulcer in patients receiving anti-platelet therapy. Aggressive survey for gastrointestinal lesions is warranted for symptomatic clopidogrel users, especially in those with history of smoking and past gastrointestinal bleeding history. 
